Preclinical News and Research

RSS

African leaders gather to discuss ways to bolster continent's drug, diagnostic development

Business Day examines efforts currently underway in Africa to bolster the continent's ability to develop new drugs and diagnostics.

7 Oct 2009

Phase 2 clinical study results of TOPICA's luliconazole for athlete's foot announced

TOPICA Pharmaceuticals, a privately-held biotechnology company, today announced positive results from its Phase 2 clinical study evaluating luliconazole, one of the most potent and broad spectrum topical antifungal agents, in patients with tinea pedis (athlete's foot). The study was designed to assess the effectiveness of 1% luliconazole cream applied once daily for 14 days compared with once daily for 28 days.

6 Oct 2009

PDS Biotechnology's Versamune-based immunotherapy drug demonstrates safety in preclinical studies

PDS Biotechnology Corporation today announced that the company has completed GLP toxicology studies of its lead HPV-cancer product. The studies, which included pharmacokinetic (PK) and adsorption, bio-distribution and excretion (ADE) studies in addition to the evaluation of toxicity, all demonstrated a very safe profile of the drug and PDS Biotech's platform Versamune((TM)) technology.

6 Oct 2009

Ground Zero Pharmaceuticals opens new office in Brisbane

A major increase in innovative concepts for exciting therapeutic and preventive new products in Australia has led to an expansion of GZP's activities Down Under, to better support clients in their efforts to take their programs to the US Food and Drug Administration.

6 Oct 2009

NIMH awards SRI International a $6.3M contract for study of ligands for brain imaging research

SRI International, an independent nonprofit research and development organization, announced today that it has been awarded a $6.3 million contract by the National Institute of Mental Health (NIMH) to conduct preclinical safety studies of promising novel ligands that will be used for brain imaging research and clinical applications.

6 Oct 2009

Promising alternative to use of live animals for drug testing

International Stem Cell Corporation, the first company to perfect a method of creating human “parthenogenetic” stem cells from unfertilized eggs, announces positive results of its collaboration with Absorption Systems to study ISCO’s stem-cell-derived human corneal tissue as an alternative to live animals for drug testing.

6 Oct 2009

MD Biosciences' new location increases capacity for in vitro services and product development

MD Biosciences (MDB), a contract research organization offering pre-clinical services and products in support of drug discovery for inflammatory and neurological diseases, relocated its U.S. office from 1000 Westgate Dr, St Paul, MN to 2575 University Ave W, St Paul, MN on October 3, 2009.

6 Oct 2009

Spinal fusion dynamic stabilization system manufacturers ordered to conduct postmarket surveillance studies

The U.S. Food and Drug Administration today ordered manufacturers of certain types of pedicle screw systems, called dynamic stabilization systems, to conduct postmarket surveillance studies to collect clinical data on a number of potential safety issues, including fusion rates and frequency of additional surgeries.

6 Oct 2009

EP-100 membrane-disrupting peptide drug for cancer being tested at TCRS

A new drug designed to "seek and destroy" common cancers such as breast, prostate, endometrial, pancreatic, ovarian, skin and testicular cancers is being tested at TGen Clinical Research Services (TCRS) at Scottsdale Healthcare.

6 Oct 2009

Allos Therapeutics to raise funds for preclinical research and clinical development of FOLOTYN

Allos Therapeutics, Inc. today announced that it is offering to sell, subject to market and other conditions, 11,000,000 primary shares of its common stock pursuant to an effective shelf registration statement in an underwritten public offering.

6 Oct 2009

Pomegranate juice beneficial for patients with elevated cardiovascular disease risk factors: Study

According to a clinical study released in The American Journal of Cardiology, a daily serving of POM Wonderful 100% Pomegranate Juice may decrease the progression of arterial plaque in patients with elevated cardiovascular disease risk factors. The study was intended to see if POM Wonderful 100% Pomegranate Juice may slow the progression of intima-media thickness of the carotid artery (CIMT) in patients with moderate coronary heart disease risk.

6 Oct 2009

ALS patients' bone marrow cells capable of differentiating into nerve-supporting cells

BrainStorm Cell Therapeutics Inc., a leading developer of adult stem cell technologies and therapeutics, announced today that bone marrow cells taken from ALS patients were capable of differentiating into nerve-supporting cells.

5 Oct 2009

LA BioMed granted $1.3M for investigating ESAI's KRONOS IV in correcting erectile dysfunction

Las Vegas-based Endogenous Stem Cells Activators Inc. (ESAI) announced today that it will award a $1.3 million grant to Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LABioMed) for pre-clinical studies aimed at activating penile endogenous (adult) stem cells with the company's drug, KRONOS IV.

5 Oct 2009

Preclinical study results of AVL-181 protease inhibitor presented

Avila Therapeutics, Inc., a biotechnology company developing novel covalent drugs that treat diseases through protein silencing, presented results of preclinical studies on its highly selective, pan-genotype, small molecule Hepatitis C Virus (HCV) protease inhibitor, AVL-181.

5 Oct 2009

Pharmatek to install the Xcelodose automated encapsulator system in San Diego

Pharmatek Laboratories, Inc., a premier contract development and manufacturing organization supporting the pharmaceutical industry, announced that it is the first CRO on the West Coast to acquire the Xcelodose system, enhancing the company's preclinical and early phase clinical GMP supply capabilities.

3 Oct 2009

Quest PharmaTech acquires immunotherapeutic antibody products from Paladin Labs

Quest PharmaTech Inc. ("Quest" or the "Company"), a pharmaceutical company developing and commercializing products for the treatment of cancer, today announced that it has acquired a pipeline of late-stage immunotherapy product candidates from Paladin Labs Inc. ("Paladin").

3 Oct 2009

Array BioPharma to present poster on ARRY-403 glucokinase activator

Array BioPharma Inc. today announced that a poster on ARRY-403, a novel, oral, glucokinase activator (GKA), will be presented at the European Association for the Study of Diabetes annual meeting, on October 2, 2009, in Vienna, Austria.

2 Oct 2009

Merrimack and sanofi-aventis collaborate to develop and co-commercialize MM-121, a monoclonal antibody

Merrimack Pharmaceuticals, Inc. and sanofi-aventis announced today the signing of an exclusive worldwide licensing agreement for the development and co-commercialization of MM-121, a first-in-class, fully human monoclonal antibody designed to block signaling of the ErbB3 receptor. MM-121 is currently in Phase 1 clinical testing.

1 Oct 2009

Phase 1 clinical trial to test safety and activity of human MAB launched in India

MassBiologics of the University of Massachusetts Medical School today announced the beginning of a Phase 1 clinical trial, testing the safety and activity of a human monoclonal antibody (MAB) developed to neutralize the rabies virus.

1 Oct 2009

Promising results from Cell Therapeutics' phase II OPAXIO study for advanced esophageal cancer

Cell Therapeutics, Inc. announced today that, in a study from Brown University to be presented by Howard Safran, M.D., head of the Brown University Oncology Group, in the proffered oral session at the Annual Meeting of the International Society of Gastrointestinal Oncology (ISGIO) in Philadelphia, Pennsylvania patients with cancer of the lower esophagus demonstrated a high rate of complete remission (CR) when given OPAXIO(TM) (paclitaxel poliglumex), a biologically enhanced paclitaxel, when administered in combination with standard cisplatin and concurrent radiation.

1 Oct 2009

Preclinical News and Research

African leaders gather to discuss ways to bolster continent's drug, diagnostic development

Phase 2 clinical study results of TOPICA's luliconazole for athlete's foot announced

PDS Biotechnology's Versamune-based immunotherapy drug demonstrates safety in preclinical studies

Ground Zero Pharmaceuticals opens new office in Brisbane

NIMH awards SRI International a $6.3M contract for study of ligands for brain imaging research

Promising alternative to use of live animals for drug testing

MD Biosciences' new location increases capacity for in vitro services and product development

Spinal fusion dynamic stabilization system manufacturers ordered to conduct postmarket surveillance studies

EP-100 membrane-disrupting peptide drug for cancer being tested at TCRS

Allos Therapeutics to raise funds for preclinical research and clinical development of FOLOTYN

Pomegranate juice beneficial for patients with elevated cardiovascular disease risk factors: Study

ALS patients' bone marrow cells capable of differentiating into nerve-supporting cells

LA BioMed granted $1.3M for investigating ESAI's KRONOS IV in correcting erectile dysfunction

Preclinical study results of AVL-181 protease inhibitor presented

Pharmatek to install the Xcelodose automated encapsulator system in San Diego

Quest PharmaTech acquires immunotherapeutic antibody products from Paladin Labs

Array BioPharma to present poster on ARRY-403 glucokinase activator

Merrimack and sanofi-aventis collaborate to develop and co-commercialize MM-121, a monoclonal antibody

Phase 1 clinical trial to test safety and activity of human MAB launched in India

Promising results from Cell Therapeutics' phase II OPAXIO study for advanced esophageal cancer

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest Life Science News